ORXOF (Orexo AB) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

What is Orexo AB LT-Debt-to-Total-Asset?

Orexo AB ORXOF 34 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Orexo AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Orexo AB's long-term debt to total assets ratio declined from Mar. 2025 (0.88) to Mar. 2026 (0.01). It may suggest that Orexo AB is progressively becoming less dependent on debt to grow their business.

Orexo AB (OTCPK:ORXOF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Orexo AB LT-Debt-to-Total-Asset Related Terms

Orexo AB LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Orexo AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB LT-Debt-to-Total-Asset Chart

Orexo AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.42

0.47

0.58

0.78

0.37

Orexo AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.88	0.89	0.92	0.37	0.01

34GF Score

Orexo AB ORXOF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Orexo AB LT-Debt-to-Total-Asset Calculation

Orexo AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	52.058	/	140.184
	=	0.37

Orexo AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.301	/	65.513
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

Orexo AB (ORXOF) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orexo AB and its competitors.

Is Orexo AB's LT-Debt-to-Total-Asset too high?

Orexo AB's current LT-Debt-to-Total-Asset is 0.01. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Orexo AB's LT-Debt-to-Total-Asset compare to ZTS?

Orexo AB's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orexo AB and its competitors. Orexo AB's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Orexo AB stock overvalued right now?

Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Orexo AB (ORXOF), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (ORXOF) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for ORXOF:

LT-Debt-to-Total-Asset: 0.01
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies OSTO:EQL OSTO:ENZY OSTO:NANEXA OSTO:CINPHA OSTO:MOB OSTO:DICOT OSTO:KLAR XSAT:ACUC OSTO:VIVE XSAT:ODI XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges ORXOY:USA ORX:Sweden 0H19:UK C5G:Germany

Address Virdings alle 22, Uppsala, SWE, 75105

Website https://www.orexo.com

Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.

34GF Score

Get the complete analysis for ORXOF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10

Price

$0.68

GF Value

View ORXOF Analysis

See LT-Debt-to-Total-Asset data for all stocks →